<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2393-6797</journal-id>
<journal-title><![CDATA[Revista Uruguaya de Medicina Interna ]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Urug. Med. Int.]]></abbrev-journal-title>
<issn>2393-6797</issn>
<publisher>
<publisher-name><![CDATA[Sociedad de Medicina Interna del Uruguay]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2393-67972026000101301</article-id>
<article-id pub-id-type="doi">10.26445/11.01.10</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Efectos adversos inmunomediados en pacientes portadores de tumores sólidos tratados con bloqueadores de puntos de control inmunológico en cuatro centros de Montevideo, Uruguay.]]></article-title>
<article-title xml:lang="en"><![CDATA[Immune-mediated adverse effects in patients with solid tumors treated with immune checkpoint blockers in four centers in Montevideo, Uruguay.]]></article-title>
<article-title xml:lang="pt"><![CDATA[Efeitos adversos imunomediados em pacientes com tumores sólidos tratados com bloqueadores de pontos de controle imunológico em quatro centros em Montevidéu, Uruguai.]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Amarillo]]></surname>
<given-names><![CDATA[Dahiana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Jeldres]]></surname>
<given-names><![CDATA[Mathías]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[Clara]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Acuña]]></surname>
<given-names><![CDATA[Sofía]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ayala]]></surname>
<given-names><![CDATA[Belén]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rivero]]></surname>
<given-names><![CDATA[Florencia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Roca]]></surname>
<given-names><![CDATA[Esteban]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sellanes]]></surname>
<given-names><![CDATA[Felipe]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Collares]]></surname>
<given-names><![CDATA[Sofía]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ghiringhelli]]></surname>
<given-names><![CDATA[Paula]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Quincke]]></surname>
<given-names><![CDATA[Milena]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rehermann]]></surname>
<given-names><![CDATA[Bruna]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ribeiro]]></surname>
<given-names><![CDATA[Macarena]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Zucca]]></surname>
<given-names><![CDATA[Milena]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gentini]]></surname>
<given-names><![CDATA[Florencia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Insagaray]]></surname>
<given-names><![CDATA[Belen]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[D´Angelo]]></surname>
<given-names><![CDATA[Javier]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rivero]]></surname>
<given-names><![CDATA[Lucia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cuello]]></surname>
<given-names><![CDATA[Mauricio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[Federico]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de la República Hospital de Clínicas. Facultad de Medicina Servicio de Oncología Clínica]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2026</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2026</year>
</pub-date>
<volume>11</volume>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_arttext&amp;pid=S2393-67972026000101301&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_abstract&amp;pid=S2393-67972026000101301&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_pdf&amp;pid=S2393-67972026000101301&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: La inmunoterapia es una estrategia clave en la terapia oncológica actual y sus indicaciones con fines curativos o paliativos siguen creciendo. Su objetivo es fortalecer la respuesta inmune efectora contra las células tumorales con un perfil de efectos adversos diferente al de los tratamientos convencionales. En este trabajo evaluamos el perfil y la frecuencia de efectos adversos inmunomediados de los inhibidores de puntos de control inmunológico (ICI), en pacientes de 4 instituciones de Montevideo.  Metodología: Estudio observacional, descriptivo, transversal y retrospectivo. Se analizaron los datos de pacientes portadores de tumores so&#769;lidos que recibieron tratamiento con inhibidores del punto de control inmunológico en cuatro centros asistenciales de Montevideo, Uruguay, en el periodo comprendido entre 2021-2024.  Resultados:  El 49,5% (n=47) de los pacientes tratados en monodroga (ICI, ICI+ICI) presentaron efectos adversos, 64,3% (n=9) de aquellos tratados con ICI en combinacio&#769;n con ITK y 67,4% (n=33) de quienes recibieron ICI en combinacio&#769;n con QT. En términos generales, el estudio evidenció que la población se comporta de forma similar a los registros publicados.  Conclusiones:  El creciente uso de los inhibidores de punto de control inmune (inmunoterapia) en el tratamiento del cáncer, trae aparejado la aparición de un nuevo tipo de efectos adversos, conocidos como efectos adversos inmuno relacionados o irAEs. En este trabajo se reportaron los efectos adversos vinculados al tratamiento con inmunoterapia en cuatro centros de Montevideo, Uruguay. El porcentaje de irAEs descrito en este estudio coincide con los reportados en los ensayos clínicos y revisiones sobre el tema.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction:  Immunotherapy is a key strategy in current cancer therapy, and its indications for curative or palliative purposes continue to grow. Its objective is to strengthen the effector immune response against tumor cells with an adverse effect profile different from that of conventional treatments. In this study, we evaluated the profile and frequency of immune-mediated adverse effects of immune checkpoint inhibitors (ICIs) in patients from four institutions in Montevideo, Uruguay.  Methodology:  This was an observational, descriptive, cross-sectional, and retrospective study. Data from patients with solid tumors who received treatment with immune checkpoint inhibitors at four healthcare centers in Montevideo, Uruguay, between 2021 and 2024 were analyzed.  Results:  49.5% (n=47) of patients treated with monotherapy (ICI, ICI+ICI) experienced adverse effects, as did 64.3% (n=9) of those treated with ICI in combination with KIs, and 67.4% (n=33) of those who received ICI in combination with chemotherapy. Overall, the study showed that the population behaved similarly to published records.  Conclusions:  The increasing use of immune checkpoint inhibitors (immunotherapy) in cancer treatment has led to the emergence of a new type of adverse effect, known as immune-related adverse events (irAEs). This study reported the adverse effects associated with immunotherapy treatment at four centers in Montevideo, Uruguay. The percentage of irAEs described in this study is consistent with those reported in clinical trials and reviews on the subject.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo  Introdução: A imunoterapia é uma estratégia fundamental no tratamento atual do câncer, e suas indicações para fins curativos ou paliativos continuam a crescer. Seu objetivo é fortalecer a resposta imune efetora contra as células tumorais, com um perfil de efeitos adversos diferente do dos tratamentos convencionais. Neste estudo, avaliamos o perfil e a frequência de efeitos adversos imunomediados de inibidores de checkpoint imunológico (ICIs) em pacientes de quatro instituições em Montevidéu, Uruguai.  Metodologia:  Trata-se de um estudo observacional, descritivo, transversal e retrospectivo. Foram analisados &#8203;&#8203;dados de pacientes com tumores sólidos que receberam tratamento com inibidores de checkpoint imunológico em quatro centros de saúde em Montevidéu, Uruguai, entre 2021 e 2024.  Resultados:  49,5% (n=47) dos pacientes tratados com monoterapia (ICI, ICI+ICI) apresentaram efeitos adversos, assim como 64,3% (n=9) daqueles tratados com ICI em combinação com inibidores de quinase (IQs) e 67,4% (n=33) daqueles que receberam ICI em combinação com quimioterapia. De modo geral, o estudo mostrou que a população se comportou de maneira semelhante aos registros publicados.  Conclusões:  O uso crescente de inibidores de checkpoint imunológico (imunoterapia) no tratamento do câncer levou ao surgimento de um novo tipo de efeito adverso, conhecido como eventos adversos relacionados à imunidade (EAI). Este estudo relatou os efeitos adversos associados ao tratamento com imunoterapia em quatro centros de Montevidéu, Uruguai. A porcentagem de EAI descrita neste estudo é consistente com a relatada em ensaios clínicos e revisões sobre o assunto.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Cáncer]]></kwd>
<kwd lng="es"><![CDATA[Toxicidad]]></kwd>
<kwd lng="es"><![CDATA[Inmunoterapia]]></kwd>
<kwd lng="es"><![CDATA[Tratamientos del cáncer.]]></kwd>
<kwd lng="en"><![CDATA[Cancer]]></kwd>
<kwd lng="en"><![CDATA[Toxicity]]></kwd>
<kwd lng="en"><![CDATA[Immunotherapy]]></kwd>
<kwd lng="en"><![CDATA[Cancer treatments.]]></kwd>
<kwd lng="pt"><![CDATA[Câncer]]></kwd>
<kwd lng="pt"><![CDATA[Toxicidade]]></kwd>
<kwd lng="pt"><![CDATA[Imunoterapia]]></kwd>
<kwd lng="pt"><![CDATA[Tratamentos contra o câncer.]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<collab>World Health Organization</collab>
<source><![CDATA[Cáncer (Internet)]]></source>
<year>2022</year>
<publisher-loc><![CDATA[Geneva ]]></publisher-loc>
<publisher-name><![CDATA[WHO]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<collab>Comisión Contra el Cáncer</collab>
<source><![CDATA[Registro Nacional del Cáncer (Internet)]]></source>
<year>2022</year>
<publisher-loc><![CDATA[Montevideo ]]></publisher-loc>
<publisher-name><![CDATA[Comisión Honoraria de Lucha Contra el Cáncer]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Hong]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Han]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Ma]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immune checkpoint therapy for solid tumours clinical dilemmas and future trends]]></article-title>
<source><![CDATA[Signal Transduct Target Ther]]></source>
<year>2023</year>
<volume>8</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>320</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martins]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Sofiya]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Sykiotis]]></surname>
<given-names><![CDATA[GP]]></given-names>
</name>
<name>
<surname><![CDATA[Lamine]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Maillard]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fraga]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adverse effects of immune-checkpoint inhibitors epidemiology, management and surveillance]]></article-title>
<source><![CDATA[Nat Rev Clin Oncol]]></source>
<year>2019</year>
<volume>16</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>563-80</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Postow]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Sidlow]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hellmann]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immune-related adverse events associated with immune checkpoint blockade]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2018</year>
<volume>378</volume>
<page-range>158-68</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Siddiqui]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Usmani]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ansari]]></surname>
<given-names><![CDATA[MN]]></given-names>
</name>
<name>
<surname><![CDATA[Almoselhy]]></surname>
<given-names><![CDATA[RIM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immune-related adverse events in immunotherapy Challenges in diagnosis, monitoring, and management]]></article-title>
<source><![CDATA[Toxicol Rep]]></source>
<year>2025</year>
<volume>14</volume>
<page-range>102036</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brahmer]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Lacchetti]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Schneider]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Atkins]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Brassil]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
<name>
<surname><![CDATA[Caterino]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy American Society of Clinical Oncology Clinical Practice Guideline]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2018</year>
<volume>36</volume>
<numero>17</numero>
<issue>17</issue>
<page-range>1714-68</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Michot]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Bigenwald]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Champiat]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Collins]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Carbonnel]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Postel-Vinay]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immune-related adverse events with immune checkpoint blockade a comprehensive review]]></article-title>
<source><![CDATA[Eur J Cancer]]></source>
<year>2016</year>
<volume>54</volume>
<page-range>139-48</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Spain]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Walls]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Julve]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[O&amp;apos;Meara]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Schmid]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Kalaitzaki]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma a single centre experience and review of the literature]]></article-title>
<source><![CDATA[Ann Oncol]]></source>
<year>2017</year>
<volume>28</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>377-85</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Puzanov]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Diab]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Abdallah]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Bingham]]></surname>
<given-names><![CDATA[CO]]></given-names>
</name>
<name>
<surname><![CDATA[Brogdon]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Dadu]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Managing toxicities associated with immune checkpoint inhibitors consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group]]></article-title>
<source><![CDATA[J Immunother Cancer]]></source>
<year>2017</year>
<volume>5</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>95</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Haanen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Obeid]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Spain]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Carbonnel]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Robert]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of toxicities from immunotherapy ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up]]></article-title>
<source><![CDATA[Ann Oncol]]></source>
<year>2022</year>
<volume>33</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1217-38</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="book">
<collab>Estados Unidos. Instituto Nacional del Cáncer</collab>
<source><![CDATA[Cáncer e inmunoterapia: investigación y efectos secundarios]]></source>
<year>2019</year>
<publisher-loc><![CDATA[s.l. ]]></publisher-loc>
<publisher-name><![CDATA[NCI]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pérez-Cárdenas]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez-Castro]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Study of the main immunomediated effects detected in a new advanced Nursing practice consultation]]></article-title>
<source><![CDATA[Ene]]></source>
<year>2022</year>
<volume>16</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chhabra]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Kennedy]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Review of Cancer Immunotherapy Toxicity Immune Checkpoint Inhibitors]]></article-title>
<source><![CDATA[J Med Toxicol]]></source>
<year>2021</year>
<volume>17</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>411-24</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Villa-Crespo]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Podlipnik]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Anglada]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Izquierdo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Giavedoni]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Iglesias]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Timeline of Adverse Events during Immune Checkpoint Inhibitors for Advanced Melanoma and Their Impacts on Survival]]></article-title>
<source><![CDATA[Cancers (Basel)]]></source>
<year>2022</year>
<volume>14</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1237</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reck]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez-Abreu]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Robinson]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
<name>
<surname><![CDATA[Hui]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Csoszi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Fülöp]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2016</year>
<volume>375</volume>
<numero>19</numero>
<issue>19</issue>
<page-range>1823-33</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baraka]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Abosheaishaa]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Nassar]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunotherapy-induced thyroid dysfunction an updated review]]></article-title>
<source><![CDATA[Egypt J Intern Med]]></source>
<year>2023</year>
<volume>35</volume>
<page-range>48</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Larkin]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chiarion-Sileni]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Gonzalez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Grob]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Cowey]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Lao]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2015</year>
<volume>373</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>23-34</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
